Literature DB >> 29956017

Heparin impairs angiogenic signaling and compensatory lung growth after left pneumonectomy.

Duy T Dao1,2, Lorenzo Anez-Bustillos1,2, Jared Ourieff1,2, Amy Pan1,2, Paul D Mitchell3, Hiroko Kishikawa1,2, Gillian L Fell1,2, Meredith A Baker1,2, Randolph S Watnick1,2, Hong Chen1,2, Thomas E Hamilton2, Michael S Rogers1,2, Diane R Bielenberg1,2, Mark Puder4,5.   

Abstract

Children with hypoplastic lung diseases, such as congenital diaphragmatic hernia, can require life support via extracorporeal membrane oxygenation and systemic anticoagulation, usually in the form of heparin. The role of heparin in angiogenesis and organ growth is inconclusive, with conflicting data reported in the literature. This study aimed to investigate the effects of heparin on lung growth in a model of compensatory lung growth (CLG). Compared to the absence of heparin, treatment with heparin decreased the vascular endothelial growth factor (VEGF)-mediated activation of VEGFR2 and mitogenic effect on human lung microvascular endothelial cells in vitro. Compared to non-heparinized controls, heparinized mice demonstrated impaired pulmonary mechanics, decreased respiratory volumes and flows, and reduced activity levels after left pneumonectomy. They also had lower lung volume, pulmonary septal surface area and alveolar density on morphometric analyses. Lungs of heparinized mice displayed decreased phosphorylation of VEGFR2 compared to the control group, with consequential downstream reduction in markers of cellular proliferation and survival. The use of bivalirudin, an alternative anticoagulant that does not interact with VEGF, preserved lung growth and pulmonary mechanics. These results demonstrated that heparin impairs CLG by reducing VEGFR2 activation. These findings raise concern for the clinical use of heparin in the setting of organ growth or regeneration.

Entities:  

Keywords:  Bivalirudin; Compensatory lung growth; Heparin; Pneumonectomy; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2018        PMID: 29956017      PMCID: PMC6463887          DOI: 10.1007/s10456-018-9628-3

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  39 in total

Review 1.  Quantitative microscopy of the lung: a problem-based approach. Part 2: stereological parameters and study designs in various diseases of the respiratory tract.

Authors:  Christian Mühlfeld; Matthias Ochs
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-05-24       Impact factor: 5.464

Review 2.  Anticoagulation and Transfusion Therapy in Patients Requiring Extracorporeal Membrane Oxygenation.

Authors:  Jesse M Raiten; Zerlina Z Wong; Audrey Spelde; James E Littlejohn; John G T Augoustides; Jacob T Gutsche
Journal:  J Cardiothorac Vasc Anesth       Date:  2016-08-10       Impact factor: 2.628

Review 3.  Heparin, heparan sulfate and heparanase in inflammatory reactions.

Authors:  Jin-Ping Li; Israel Vlodavsky
Journal:  Thromb Haemost       Date:  2009-11       Impact factor: 5.249

Review 4.  Heparan sulfate in skeletal development, growth, and pathology: the case of hereditary multiple exostoses.

Authors:  Julianne Huegel; Federica Sgariglia; Motomi Enomoto-Iwamoto; Eiki Koyama; John P Dormans; Maurizio Pacifici
Journal:  Dev Dyn       Date:  2013-07-29       Impact factor: 3.780

5.  Pneumonectomy in the mouse: technique and perioperative management.

Authors:  Maromi K Sakurai; Arin K Greene; Jay Wilson; Dario Fauza; Mark Puder
Journal:  J Invest Surg       Date:  2005 Jul-Aug       Impact factor: 2.533

Review 6.  The story of the discovery of heparin and warfarin.

Authors:  Douglas Wardrop; David Keeling
Journal:  Br J Haematol       Date:  2008-03-18       Impact factor: 6.998

Review 7.  Heparan sulfate: a key regulator of embryonic stem cell fate.

Authors:  Daniel C Kraushaar; Stephen Dalton; Lianchun Wang
Journal:  Biol Chem       Date:  2013-06       Impact factor: 3.915

8.  Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor.

Authors:  D Coltrini; M Rusnati; G Zoppetti; P Oreste; G Grazioli; A Naggi; M Presta
Journal:  Biochem J       Date:  1994-10-15       Impact factor: 3.857

9.  Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization.

Authors:  Bi-Sen Ding; Daniel J Nolan; Peipei Guo; Alexander O Babazadeh; Zhongwei Cao; Zev Rosenwaks; Ronald G Crystal; Michael Simons; Thomas N Sato; Stefan Worgall; Koji Shido; Sina Y Rabbany; Shahin Rafii
Journal:  Cell       Date:  2011-10-28       Impact factor: 41.582

Review 10.  Diverse Roles of Heparan Sulfate and Heparin in Wound Repair.

Authors:  Pawel Olczyk; Łukasz Mencner; Katarzyna Komosinska-Vassev
Journal:  Biomed Res Int       Date:  2015-07-07       Impact factor: 3.411

View more
  3 in total

1.  New anti-angiogenic compound based on chemically modified heparin.

Authors:  Vinicius Kniggendorf; Maria Eduarda Perrud Souza; Thatiane Russo; Marcelo Andrade de Lima; Alex Treiger Grupenmacher; Caio V Regatieri; Juliana L Dreyfuss
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-09-13       Impact factor: 3.535

2.  Investigation of the mechanisms of VEGF-mediated compensatory lung growth: the role of the VEGF heparin-binding domain.

Authors:  Lumeng J Yu; Victoria H Ko; Duy T Dao; Jordan D Secor; Amy Pan; Bennet S Cho; Paul D Mitchell; Hiroko Kishikawa; Diane R Bielenberg; Mark Puder
Journal:  Sci Rep       Date:  2021-06-04       Impact factor: 4.379

3.  Lipopolysaccharide-induced murine lung injury results in long-term pulmonary changes and downregulation of angiogenic pathways.

Authors:  S T Tsikis; S C Fligor; T I Hirsch; A Pan; L J Yu; H Kishikawa; M M Joiner; P D Mitchell; M Puder
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.